Oxford Biomedica plc (LON:OXB)
552.00
+7.00 (1.28%)
Nov 4, 2026, 5:11 PM GMT
Oxford Biomedica Market Cap
Oxford Biomedica has a market cap or net worth of 668.13 million as of November 4, 2026. It is the 10,589th most valuable company in the world and the 251st biggest in the United Kingdom. Its market cap has decreased by 15.22% in one year.
Market Cap
668.13M
Enterprise Value
751.49M
Revenue
175.36M
Global Rank
Country Rank
#251 United Kingdom
PE Ratio
n/a
ChartMarket Cap Chart
Since September 22, 1997, Oxford Biomedica's market cap has increased from 17.39M to 668.13M, an increase of 3,741.23%. That is a compound annual growth rate of 13.34%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 4, 2026 | 668.13M | -10.16% |
| Dec 31, 2025 | 743.72M | 67.15% |
| Dec 31, 2024 | 444.94M | 108.92% |
| Dec 29, 2023 | 212.97M | -50.00% |
| Dec 30, 2022 | 425.96M | -59.79% |
| Dec 31, 2021 | 1.06B | 24.98% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Oxford Nanopore Technologies | 2.10B |
| Genus | 1.53B |
| PureTech Health | 304.02M |
| Avacta Group | 279.90M |
| Bioventix | 107.11M |
| Scancell Holdings | 104.74M |
| 4basebio | 77.69M |
| Faron Pharmaceuticals Oy | 62.99M |